Bolt Biotherapeutics
BOLT
37 hedge funds and large institutions have $33.6M invested in Bolt Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.59% less ownership
Funds ownership: 63.54% → 62.95% (-0.59%)
5% less funds holding
Funds holding: 39 → 37 (-2)
21% less capital inflows, than outflows
Capital inflows: $507K | Capital outflows: $646K
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$170K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$123K |
| 3 |
Renaissance Technologies
New York
|
+$83.8K |
| 4 |
Acuitas Investments
Seattle,
Washington
|
+$67.7K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$26.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
-$269K |
| 2 |
Privium Fund Management (UK)
London,
United Kingdom
|
-$130K |
| 3 |
Morgan Stanley
New York
|
-$63.4K |
| 4 |
Jane Street
New York
|
-$63K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$50.1K |
BOLT Hedge Fund Activity: Q1 2024 in Review
37 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2024, worth a combined $33.6M — up 24% from $27M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BOLT and 2 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Newtyn Management, adding an estimated $170K. The largest seller was Tang Capital Management, cutting an estimated $269K.
- 37 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2024, down from 39 in Q4 2023.
- Funds reported $33.6M of Bolt Biotherapeutics stock for Q1 2024, up 24% quarter-over-quarter.
- 2 funds opened new Bolt Biotherapeutics positions in Q1 2024 and 4 closed out, a net change of -2 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2024 was Newtyn Management, an estimated $170K added.
- The largest Bolt Biotherapeutics seller in Q1 2024 was Tang Capital Management, an estimated $269K sold.
Based on aggregated 13F filings for Q1 2024.